Live
- Activist Alleges CPCB Cover-up on Endosulfan in Kasaragod
- Theft Case of Thumbe Mahalingeshwara Temple
- DIY vs professional car detailing: Pros and Cons
- Wild Elephant Gets Stuck at Rail Track Fence Forest Department Frees Animal
- CERT-In Issues Critical Security Alert for Apple Users: Update Your Devices Now
- Kolar’s Compassionate Leap: Mechanical Elephant Leads Temple Procession
- Centre to unveil startups under new National Quantum Mission guidelines
- Women’s protest rally in Imphal against re-imposition of AFSPA in 6 police station areas
- Greater Nicobar Island project has all environmental clearances: Govt
- Fadnavis leaves for Delhi, expected to meet Amit Shah along with Shinde, Ajit Pawar
Gilead scouting for partners in India for Remdesivir drug
USFDA has given 'Emergency Use Authorisation' for the drug after positive results in clinical trials on Covid-19 patients in US
Hyderabad: US-based Gilead Sciences has said it is in talks with Indian and Pakistan pharmaceutical companies to produce Remdesivir for developing countries. Remdesivir is an investigational antiviral drug that may be found effective against the virus that causes Covid-19, Gilead said in a statement on Wednesday.
Recent clinical trial results and the decision by the US Food and Drug Administration (USFDA) to issue 'Emergency Use Authorisation' for Remdesvir have highlighted the urgency of this work and the importance of planning for access to the drug globally, it said.
The company is also negotiating for long-term voluntary licences with several generic drug-makers in India and Pakistan to produce the medicine for developing countries. The drug maker would provide appropriate technology transfers to facilitate this production. Finally, the company is in discussion with the Medicines Patent Pool, which Gilead has partnered with for many years, to license Remdesivir for developing countries, the drug-maker said.
The company is in discussions with some of the world's leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licences, to produce it for Europe, Asia and the developing world through at least 2022.
To further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilise their vast experience in providing medicines to low- and middle-income countries during emergency and humanitarian crises to deliver the drug using its distribution networks.
As the close coordination of the drug manufacturing is critical, the USA pharmaceutical major is working to build a consortium of manufacturing partners to bring efforts together to help maximise global supply.
Producing the drug requires scarce raw materials, with their own lengthy production time, and specialised manufacturing capabilities with limited global capacity.
